Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. [electronic resource]
Producer: 20110321Description: 137-43 p. digitalISSN:- 1573-7217
- Adult
- Aged
- Anastrozole
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Aromatase Inhibitors -- administration & dosage
- Benzenesulfonates -- administration & dosage
- Breast Neoplasms -- chemistry
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Endothelial Cells -- drug effects
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Niacinamide -- analogs & derivatives
- Nitriles -- administration & dosage
- Phenylurea Compounds
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Receptors, Estrogen -- analysis
- Receptors, Progesterone -- analysis
- Sorafenib
- Stem Cells -- drug effects
- Time Factors
- Treatment Outcome
- Triazoles -- administration & dosage
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.